61 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22663 | 2nd to 6th line / at least 1 measurable imaging lesion >=2,0cm /archived or fresh biopsy available / no prior treatment with BCL2 inhibitors | Dominique Bron | Lymphoma | Pharmacyclics, Inc. | SYMPATICO | Trial closed for recruitment | Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma | dominique.bron@hubruxelles.be | 3 | 3 | |
| 22677 | - prior anti-myeloma treatment included both a PI- and lenalidomide-containing regimens - no previous therapy with Pomalidomide nor CD-38 MoAb |
Nathalie Meuleman | Myeloma | EMN | The APOLLO Study | Trial closed for recruitment | A phase III Study comparing Pomalidomide and Dexamethasone with or without Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy with both Lenalidomide and a Proteasome Inhibitor | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 22635 | relapsed or refractory AML / MDS with R-IPSS ? 2 with failure to prior treatment/ not eligible for standard of care therapy | Ahmad Hussein Awada | Multiple | Celyad | THINK | Trial closed | A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 29425 | Progression on last line of treatment, no other therapeutic option | Nathalie Meuleman | Myeloma | iTeos | TIG-007 | Trial open for recruitment | Study of EOS884448 alone, and in combination with iberdomide with or without dexamethasone, in participants with relapse or refractory multiple myeloma (TIG-007) | nathalie.meuleman@hubruxelles.be | 1/2 | 1 | |
| 22674 | CD30 positive Peripheral T-cell Lymphoma/Ann Arbor stage I-IV/at least 1 measurable lesion >=1,5cm | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | TOTAL | Trial closed | A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance (TOTAL) | marie.maerevoet@hubruxelles.be | 2 | 2 |